TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025

TriSalus Life Sciences, Inc.

2024-FY EPS reported -$1.31 revenue$29,431,000

Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.
Q4 operating cash flow (~$5.6M) improved from (~$10.8M) in Q3.
Expects positive full-year EBITDA in 2025 and positive cash flow during H2 2025.
Cash ~$8.5M; expects to qualify for additional $10M debt tranche from OrbiMed in Q1 2025.
Revenue growth guidance for 2025: in excess of 50%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.